Alector (NASDAQ:ALEC – Get Rating) had its price target reduced by research analysts at Mizuho from $15.00 to $12.00 in a research note issued on Friday, The Fly reports. Mizuho’s price objective would indicate a potential upside of 52.09% from the stock’s current price.
A number of other brokerages have also weighed in on ALEC. BTIG Research cut their price objective on Alector from $54.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday. TheStreet downgraded Alector from a “c-” rating to a “d” rating in a research note on Friday, November 11th. HC Wainwright reiterated a “buy” rating and set a $41.00 target price on shares of Alector in a research report on Wednesday. Bank of America cut shares of Alector from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $24.00 to $12.00 in a research report on Friday, January 6th. Finally, Morgan Stanley decreased their price target on shares of Alector from $13.00 to $11.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 24th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Alector presently has a consensus rating of “Hold” and an average target price of $15.67.
Alector Stock Performance
ALEC opened at $7.89 on Friday. The stock has a market capitalization of $655.11 million, a price-to-earnings ratio of -4.90 and a beta of 0.83. Alector has a fifty-two week low of $6.84 and a fifty-two week high of $15.72. The company has a fifty day moving average of $8.96 and a 200 day moving average of $9.11.
Insider Buying and Selling at Alector
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new position in Alector in the 1st quarter worth about $25,000. Great West Life Assurance Co. Can bought a new position in Alector in the third quarter worth approximately $27,000. Lazard Asset Management LLC increased its holdings in Alector by 99.2% during the 2nd quarter. Lazard Asset Management LLC now owns 6,231 shares of the company’s stock worth $63,000 after purchasing an additional 3,103 shares during the period. Point72 Hong Kong Ltd bought a new stake in Alector during the 3rd quarter valued at $65,000. Finally, Alpine Global Management LLC purchased a new stake in shares of Alector in the 4th quarter worth $93,000. Hedge funds and other institutional investors own 64.96% of the company’s stock.
Alector, Inc operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies.
- Get a free copy of the StockNews.com research report on Alector (ALEC)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.